Literature DB >> 19485798

Impaired fitness of drug-resistant malaria parasites: evidence and implication on drug-deployment policies.

Hamza A Babiker1, Ian M Hastings, Göte Swedberg.   

Abstract

Malaria, a leading parasitic disease, inflicts an enormous toll on human lives and is caused by protozoal parasites belonging to the genus Plasmodium. Antimalarial drugs targeting essential biochemical processes in the parasite are the primary resources for management and control. However, the parasite has established mutations, substantially reducing the efficacy of these drugs. First-line therapy is faced the with the consistent evolution of drug-resistant genotypes carrying these mutations. However, drug-resistant genotypes are likely to be less fit than the wild-type, suggesting that they might disappear by reducing the volume of drug pressure. A substantial body of epidemiological evidence confirmed that the frequency of resistant genotypes wanes when active drug selection declines. Drug selection on the parasite genome that removes genetic variation in the vicinity of drug-resistant genes (hitch-hiking) is common among resistant parasites in the field. This can further disadvantage drug-resistant strains and limit their variability in the face of a mounting immune response. Attempts to provide unequivocal evidence for the fitness cost of drug resistance have monitored the outcomes of laboratory competition experiments of deliberate mixtures of sensitive and resistant strains, in the absence of drug pressure, using isogenic clones produced either by drug selection or gene manipulation. Some of these experiments provided inconclusive results, but they all suggested reduced fitness of drug-resistant clones in the absence of drug pressure. In addition, biochemical analyses provided clearer information demonstrating that the mutation of some antimalarial-targeted enzymes lowers their activity compared with the wild-type enzyme. Here, we review current evidences for the disadvantage of drug-resistance mutations, and discuss some strategies of drug deployment to maximize the cost of resistance and limit its spread.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19485798     DOI: 10.1586/eri.09.29

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  29 in total

1.  Superinfection and the evolution of resistance to antimalarial drugs.

Authors:  Eili Y Klein; David L Smith; Ramanan Laxminarayan; Simon Levin
Journal:  Proc Biol Sci       Date:  2012-07-11       Impact factor: 5.349

2.  Refugia and the evolutionary epidemiology of drug resistance.

Authors:  Andrew W Park; James Haven; Ray Kaplan; Sylvain Gandon
Journal:  Biol Lett       Date:  2015-11       Impact factor: 3.703

3.  The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy.

Authors:  Andrew F Read; Troy Day; Silvie Huijben
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-20       Impact factor: 11.205

4.  Within-host competition and drug resistance in the human malaria parasite Plasmodium falciparum.

Authors:  Mary Bushman; Lindsay Morton; Nancy Duah; Neils Quashie; Benjamin Abuaku; Kwadwo A Koram; Pedro Rafael Dimbu; Mateusz Plucinski; Julie Gutman; Peter Lyaruu; S Patrick Kachur; Jacobus C de Roode; Venkatachalam Udhayakumar
Journal:  Proc Biol Sci       Date:  2016-03-16       Impact factor: 5.349

5.  The impact of heterogeneous transmission on the establishment and spread of antimalarial drug resistance.

Authors:  Eili Y Klein
Journal:  J Theor Biol       Date:  2013-09-25       Impact factor: 2.691

6.  Environmental, pharmacological and genetic influences on the spread of drug-resistant malaria.

Authors:  Tiago Antao; Ian M Hastings
Journal:  Proc Biol Sci       Date:  2010-11-17       Impact factor: 5.349

7.  Schistosoma mansoni population structure and persistence after praziquantel treatment in two villages of Bahia, Brazil.

Authors:  Ronald E Blanton; Walter A Blank; Jackson M Costa; Theomira M Carmo; Eliana A Reis; Luciano K Silva; Lúcio M Barbosa; Matthew R Test; Mitermayer G Reis
Journal:  Int J Parasitol       Date:  2011-07-13       Impact factor: 3.981

8.  Tracking origins and spread of sulfadoxine-resistant Plasmodium falciparum dhps alleles in Thailand.

Authors:  Md Tauqeer Alam; Sumiti Vinayak; Kanungnit Congpuong; Chansuda Wongsrichanalai; Wichai Satimai; Laurence Slutsker; Ananias A Escalante; John W Barnwell; Venkatachalam Udhayakumar
Journal:  Antimicrob Agents Chemother       Date:  2010-10-18       Impact factor: 5.191

9.  The probability of evolutionary rescue: towards a quantitative comparison between theory and evolution experiments.

Authors:  Guillaume Martin; Robin Aguilée; Johan Ramsayer; Oliver Kaltz; Ophélie Ronce
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-01-19       Impact factor: 6.237

10.  Molecular surveillance for drug-resistant Plasmodium falciparum in clinical and subclinical populations from three border regions of Burma/Myanmar: cross-sectional data and a systematic review of resistance studies.

Authors:  Tyler Brown; Linda S Smith; Eh Kalu Shwe Oo; Kum Shawng; Thomas J Lee; David Sullivan; Chris Beyrer; Adam K Richards
Journal:  Malar J       Date:  2012-09-19       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.